XML Template (2009) [5.9.2009–3:06pm] [1–12]
{TANDF_FPP}CMO/CMO_A_370883(NEW).3d (CMO) [First Proof]
Current Medical Research and Opinion
C213
Volume 25, Number 3 2008
—
4.8
—
4.8
33.3
—
2.6
—
20.0
7.0
3/4
(%)
Thrombocytopenia
Grade
toxicity
4)
(Grade
—
Neutropenia
93.5
7.9
21.9 95.8 33.3 21.0
7.7
55.0 17.0
Overall
survival
21.5 22.3
—
10.8
20.1
— —
15.0
—
21.2
(months)
(%)
—
Stable
48 54.1 31.2 45.0 10.3 31.8 20.0 42.0
disease
survival — —
(weeks)
38.4 24.8
—
12.0 20.8
5.8
—
Progression- free
(%)
RR
32.6 23.8 31.3 20.9
23.8
13.6 10.3
9.1
10.0 24.0
line
of
line
line line line line line line line line
time
at
therapy
First
Treatment
Second Second Second Second Second Second Second Second
cancer.
3
n
ovarian (48/0)
platinum)
(0/24) (0/21) (29/0) (39/0) (0/22) (8/12) (38/0)
of
(35/28)
48
63
(15/14; 24 21 29 39 22 20 41
Patients, (
platinum-
sensitive/ resistant) 32
previous
treatment
no
weekly.
the
qw:
in
3-
and
a
and and
days;
daily
8,
q3w
q7d
8, 8,
7
regimens
1,
infusion
by
3
bolus
for 1, 1,
dose
i.v.
2 every
infusion q3w days
bolus 2
15,
4
2
followed
of
infusion days days
weekly weekly
q7d:
i.v. i.v.
mg/m
and
i.v. i.v. i.v. i.v., i.v.,
topotecan
2 2
mg/m
2 2 2 2 2
Regimen:
days,
5
q4w
mg/m 1–5,
interval
4.0
8
out
1.5
1, q4w q4w
weeks;
mg/m
for
mg/m
15, days week day weeks
mg/m mg/m
15,
mg/m
15,
mg/m mg/m
3
weekly
1.5 4.0 1.5–6.0 Daily: Weekly: 4.0 4.0 4.0 4.0 4.0
and
every
37 35
q3w:
daily
18
of
.,
.,
.,
.,
al
2007
al
.,
al
2008
40 al
2008
rate;
., et
al
et
.,
al
et .,
al
Trials
et
17
al
et
36 38 39
et
et
,
2007
23
3.
al
et
2000 2001 2007 2007
et
2007
response
Study McGuire Safra Homesley Largillier Spannuth Brown Le Vandenput Morris RR:
Table
!
2009 Informa UK Ltd www.cmrojournal.com Topotecan for relapsed ovarian cancer Sehouli & Oskay-O
¨
zcelik
7
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34